KLI
Login
OAK 국가리포지터리
검색
커뮤니티
제목
저자
키워드
발행일
Ulsan Univ. Repository
Browsing by 키워드 : pembrolizumab
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
가
나
다
라
마
바
사
아
자
차
카
타
파
하
All
가
나
다
라
마
바
사
아
자
차
카
타
파
하
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
또는 첫 단어:
정렬 기준:
제목
발행일
제출일
정렬:
오름차순
내림차순
결과 수
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
저자 수
All
1
3
5
10
15
20
25
30
35
40
45
50
전체 결과 9건 중 1-9 번을 표시중입니다.
1
Article
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial
Sun Young Rha
;
Toni K Choueiri
;
Vsevolod B Matveev
;
et al
2023
2
Article
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar
;
D E Castellano
;
P Grivas
;
et al
2023
3
Article
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
류백렬
;
Abby B Siegel
;
Amit S Kulkarni
;
et al
2021
4
Article
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer
Thierry André
;
Filippo Pietrantonio
;
Antonio Avallone
;
et al
2023
5
Article
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
Takayuki Yoshino
;
Thierry Andre
;
Tae Won Kim
;
et al
2023
6
Article
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
A.T.C. Chan
;
V.H.F. Lee
;
R.-L. Hong
;
et al
2023
7
Article
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia
S-B Kim
;
C Bai
;
C-H Hsu
;
et al
2022
8
Article
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
Hyun Cheol Chung
;
Yoon-Koo Kang
;
Zhendong Chen
;
et al
2022
9
Article
Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial
Hyung Jun Park
;
Yong Man Kim
;
Jae Seob Jung
;
et al
2022
1
Anonymous
Login
커뮤니티
제목
저자
키워드
발행일
Guide